

Hereditary Angioedema Drug-EMEA Market Status and Trend Report 2013-2023

https://marketpublishers.com/r/HDF8120518FMEN.html

Date: February 2018

Pages: 153

Price: US\$ 3,480.00 (Single User License)

ID: HDF8120518FMEN

Abstracts

Report Summary

Hereditary Angioedema Drug-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Hereditary Angioedema Drug industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Hereditary Angioedema Drug 2013-2017, and development forecast 2018-2023

Main market players of Hereditary Angioedema Drug in EMEA, with company and product introduction, position in the Hereditary Angioedema Drug market Market status and development trend of Hereditary Angioedema Drug by types and applications

Cost and profit status of Hereditary Angioedema Drug, and marketing status Market growth drivers and challenges

The report segments the EMEA Hereditary Angioedema Drug market as:

EMEA Hereditary Angioedema Drug Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe Middle East Africa



EMEA Hereditary Angioedema Drug Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

By Product
C1 Esterase Inhibitor
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist
By Route of Administration
Oral
Intravenous
Subcutaneous Injection

EMEA Hereditary Angioedema Drug Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Retail Pharmacies
Hospital Pharmacies
Online Pharmacies

EMEA Hereditary Angioedema Drug Market: Players Segment Analysis (Company and Product introduction, Hereditary Angioedema Drug Sales Volume, Revenue, Price and Gross Margin):

Pharming Group NV
Shire plc
CSL Limited
iBio Inc.
BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



Contents

CHAPTER 1 OVERVIEW OF HEREDITARY ANGIOEDEMA DRUG

- 1.1 Definition of Hereditary Angioedema Drug in This Report
- 1.2 Commercial Types of Hereditary Angioedema Drug
 - 1.2.1 By Product
 - 1.2.2 C1 Esterase Inhibitor
 - 1.2.3 Kallikrein Inhibitor
 - 1.2.4 Selective Bradykinin B2 Receptor Antagonist
- 1.2.5 By Route of Administration
- 1.2.6 Oral
- 1.2.7 Intravenous
- 1.2.8 Subcutaneous Injection
- 1.3 Downstream Application of Hereditary Angioedema Drug
 - 1.3.1 Retail Pharmacies
 - 1.3.2 Hospital Pharmacies
 - 1.3.3 Online Pharmacies
- 1.4 Development History of Hereditary Angioedema Drug
- 1.5 Market Status and Trend of Hereditary Angioedema Drug 2013-2023
 - 1.5.1 EMEA Hereditary Angioedema Drug Market Status and Trend 2013-2023
 - 1.5.2 Regional Hereditary Angioedema Drug Market Status and Trend 2013-2023

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Hereditary Angioedema Drug in EMEA 2013-2017
- 2.2 Consumption Market of Hereditary Angioedema Drug in EMEA by Regions
- 2.2.1 Consumption Volume of Hereditary Angioedema Drug in EMEA by Regions
- 2.2.2 Revenue of Hereditary Angioedema Drug in EMEA by Regions
- 2.3 Market Analysis of Hereditary Angioedema Drug in EMEA by Regions
 - 2.3.1 Market Analysis of Hereditary Angioedema Drug in Europe 2013-2017
 - 2.3.2 Market Analysis of Hereditary Angioedema Drug in Middle East 2013-2017
 - 2.3.3 Market Analysis of Hereditary Angioedema Drug in Africa 2013-2017
- 2.4 Market Development Forecast of Hereditary Angioedema Drug in EMEA 2018-2023
- 2.4.1 Market Development Forecast of Hereditary Angioedema Drug in EMEA 2018-2023
- 2.4.2 Market Development Forecast of Hereditary Angioedema Drug by Regions 2018-2023



CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole EMEA Market Status by Types
 - 3.1.1 Consumption Volume of Hereditary Angioedema Drug in EMEA by Types
 - 3.1.2 Revenue of Hereditary Angioedema Drug in EMEA by Types
- 3.2 EMEA Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in Europe
 - 3.2.2 Market Status by Types in Middle East
 - 3.2.3 Market Status by Types in Africa
- 3.3 Market Forecast of Hereditary Angioedema Drug in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Hereditary Angioedema Drug in EMEA by Downstream Industry
- 4.2 Demand Volume of Hereditary Angioedema Drug by Downstream Industry in Major Countries
- 4.2.1 Demand Volume of Hereditary Angioedema Drug by Downstream Industry in Europe
- 4.2.2 Demand Volume of Hereditary Angioedema Drug by Downstream Industry in Middle East
- 4.2.3 Demand Volume of Hereditary Angioedema Drug by Downstream Industry in Africa
- 4.3 Market Forecast of Hereditary Angioedema Drug in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF HEREDITARY ANGIOEDEMA DRUG

- 5.1 EMEA Economy Situation and Trend Overview
- 5.2 Hereditary Angioedema Drug Downstream Industry Situation and Trend Overview

CHAPTER 6 HEREDITARY ANGIOEDEMA DRUG MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

- 6.1 Sales Volume of Hereditary Angioedema Drug in EMEA by Major Players
- 6.2 Revenue of Hereditary Angioedema Drug in EMEA by Major Players
- 6.3 Basic Information of Hereditary Angioedema Drug by Major Players
- 6.3.1 Headquarters Location and Established Time of Hereditary Angioedema Drug Major Players



- 6.3.2 Employees and Revenue Level of Hereditary Angioedema Drug Major Players
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 HEREDITARY ANGIOEDEMA DRUG MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 7.1 Pharming Group NV
 - 7.1.1 Company profile
- 7.1.2 Representative Hereditary Angioedema Drug Product
- 7.1.3 Hereditary Angioedema Drug Sales, Revenue, Price and Gross Margin of Pharming Group NV
- 7.2 Shire plc
 - 7.2.1 Company profile
 - 7.2.2 Representative Hereditary Angioedema Drug Product
- 7.2.3 Hereditary Angioedema Drug Sales, Revenue, Price and Gross Margin of Shire plc
- 7.3 CSL Limited
 - 7.3.1 Company profile
 - 7.3.2 Representative Hereditary Angioedema Drug Product
- 7.3.3 Hereditary Angioedema Drug Sales, Revenue, Price and Gross Margin of CSL Limited
- 7.4 iBio Inc.
 - 7.4.1 Company profile
 - 7.4.2 Representative Hereditary Angioedema Drug Product
- 7.4.3 Hereditary Angioedema Drug Sales, Revenue, Price and Gross Margin of iBio Inc.
- 7.5 BioCryst Pharmaceuticals, Inc.
 - 7.5.1 Company profile
 - 7.5.2 Representative Hereditary Angioedema Drug Product
- 7.5.3 Hereditary Angioedema Drug Sales, Revenue, Price and Gross Margin of BioCryst Pharmaceuticals, Inc.
- 7.6 Ionis Pharmaceuticals, Inc.
 - 7.6.1 Company profile
 - 7.6.2 Representative Hereditary Angioedema Drug Product
- 7.6.3 Hereditary Angioedema Drug Sales, Revenue, Price and Gross Margin of Ionis Pharmaceuticals, Inc.



CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF HEREDITARY ANGIOEDEMA DRUG

- 8.1 Industry Chain of Hereditary Angioedema Drug
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF HEREDITARY ANGIOEDEMA DRUG

- 9.1 Cost Structure Analysis of Hereditary Angioedema Drug
- 9.2 Raw Materials Cost Analysis of Hereditary Angioedema Drug
- 9.3 Labor Cost Analysis of Hereditary Angioedema Drug
- 9.4 Manufacturing Expenses Analysis of Hereditary Angioedema Drug

CHAPTER 10 MARKETING STATUS ANALYSIS OF HEREDITARY ANGIOEDEMA DRUG

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
- 12.2.1 Secondary Sources



12.2.2 Primary Sources12.3 Reference



I would like to order

Product name: Hereditary Angioedema Drug-EMEA Market Status and Trend Report 2013-2023

Product link: https://marketpublishers.com/r/HDF8120518FMEN.html

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/HDF8120518FMEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970